Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice.

Abstract

BACKGROUND CCR5 plays an important role in atherosclerosis and ischemic cardiovascular diseases, as well as in HIV replication and diffusion. HIV infection is characterized by a high burden of cardiovascular diseases, particularly in subjects exposed to ritonavir-boosted protease inhibitors. Maraviroc, a CCR5 antagonist antiretroviral drug, might provide… (More)
DOI: 10.1161/CIRCULATIONAHA.113.001278

Topics

7 Figures and Tables

Cite this paper

@article{Cipriani2013EfficacyOT, title={Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice.}, author={Sabrina Cipriani and Daniela Francisci and Andrea Mencarelli and Barbara Renga and Elisabetta Schiaroli and Claudio D'Amore and Franco Baldelli and Stefano Fiorucci}, journal={Circulation}, year={2013}, volume={127 21}, pages={2114-24} }